PhD Project in Biliary Atresia Research: The University of Southern Denmark is offering a PhD scholarship within the field of biomarker and therapeutic target investigations in biliary atresia. This PhD project aims to enhance understanding and treatment of biliary atresia, a serious liver disease in infants.
Designation
PhD Candidate
Table
| Category | Details |
|---|---|
| Research Area | Biomarker and therapeutic target investigations in biliary atresia |
| Location | Department of Molecular Medicine, University of Southern Denmark, Odense M, Denmark |
| Eligibility/Qualification | – Master’s degree (or equivalent) in medicine, biomedical sciences, or related field – Experience or strong interest in experimental lab work – Basic knowledge in cell and molecular biology, immunology or pathology – Interest in liver biology, fibrosis or pediatric diseases – Skills in data analysis and statistics – Ability to work independently and collaboratively – Good English skills |
| Salary | Base salary of DKK 374,912.98 (excluding 18.07% pension contribution) |
Description
Biliary atresia (BA) is a rare but severe cholestatic liver disease that often results in the need for pediatric liver transplantation. This project will explore the mechanisms of liver fibrosis in BA, focusing on extracellular matrix-related processes. The PhD candidate will engage with clinical data, perform biomarker analyses, and carry out mechanistic studies using a neonatal large-animal model. This interdisciplinary project encourages close collaboration between different institutions and offers extensive training in translational liver research.
How to Apply
Interested candidates must submit the following:
- A letter detailing interest, motivation, and qualifications (max. 2 pages)
- A detailed CV including personal contact information
- Certified copy of diploma (Master’s degree in a relevant field)
Applications must be submitted electronically via the university’s application portal in Adobe PDF format.
Last Date to Apply
Applications must be submitted by March 1, 2026.
